CD274 and neoplasm: While there are several tumor-based biomarkers predicting response to immune therapy, such as percent of tumor PDL1 expression4 and more recently tumor mutational burden and T cell-inflamed gene expression profiling,5 identifying biomarkers to predict toxicity to cancer treatment has been limited.6 Notably, toxicity to immune therapy occurs in 25%–30% of patients regardless of cancer type, even in non-responding tumor types, supporting the hypothesis that toxicity is patient-specific and not tumor type-dependent.